Atezolizumab/cabozantinib combo effective in high-risk mCRPC
The results included data for 132 patients, all of whom had prior enzalutamide and/or abiraterone acetate.
Related Articles
Experts share their key takeaways from AUA 2024
In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.
Vibegron improves overactive bladder symptoms in pharmacologically treated BPH
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
Dr. Braun and Dr. Kenney on unmet needs in kidney cancer
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
FDA accepts BLA for subcutaneous nivolumab in solid tumors
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data show high darolutamide use for mHSPC in community urology setting
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
AUA
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Dr. Psutka describes a study of at-home prehabilitation in MIBC
Sarah P. Psutka, MD, MSc, shares the rationale for the “Get Moving Trial,” exploring at-home prehabilitation for patients with muscle-invasive bladder cancer.
Response to UGN-101 induction linked to favorable RFS in UTUC
UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to…
Dr. Li on the design of the phase 3 MoonRISe-1 trial in NMIBC
“So, in the MoonRISe-1 study, we’re studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every…
Urethral lift is superior to medical therapy in efficacy, patient experience
Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.